mTORC2 Inhibition Improves Morphological Effects of PTEN Loss, But Does Not Correct Synaptic Dysfunction or Prevent

Erin R Cullen1, Kamran Tariq2, Amy N Shore1,3

  • 1Department of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, Vermont 05405.

Insights

Genetic inactivation of mTORC2 did not prevent seizures in a mouse model of PTEN loss, despite improving cellular abnormalities. Synaptic dysfunction, not just cell morphology, drives epilepsy in this model.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Hyperactivation of PI3K/PTEN-mTOR signaling is implicated in focal cortical dysplasia, autism, and epilepsy.
  • PTEN loss of function (LOF) leads to hyperactive mTOR signaling through both mTORC1 and mTORC2 complexes.

Purpose of the Study:

  • To investigate if genetic inactivation of mTORC2 can rescue morphologic and electrophysiologic abnormalities in the dentate gyrus caused by PTEN LOF.
  • To determine if mTORC2 inactivation prevents generalized seizures in a mouse model of PTEN LOF.

Main Methods:

  • Utilized an established mouse model with early postnatal PTEN loss in male and female mice.
  • Genetically inactivated the mTORC2 complex by deleting the Rictor gene.
  • Assessed morphologic, electrophysiologic, and seizure phenotypes.

Main Results:

  • mTORC2 inactivation did not prevent spontaneous seizures despite normalizing or ameliorating many morphologic and electrophysiologic phenotypes.
  • Increased excitatory connectivity near dentate gyrus granule neuron somas was not normalized.
  • mTORC2 inactivation rescued dendritic arbor overgrowth but increased synaptic strength and impaired presynaptic function.

Conclusions:

  • Seizures downstream of PTEN LOF can be driven by increased excitatory connectivity and synaptic dysfunction, independent of characteristic morphologic changes.
  • Targeting mTORC2 alone is insufficient to prevent seizures in this model.
  • Future epilepsy therapies should focus on synaptic dysfunction mechanisms linked to PI3K/PTEN-mTOR hyperactivation.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
399